Literature DB >> 10725711

IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis.

D A Young1, L D Lowe, S S Booth, M J Whitters, L Nicholson, V K Kuchroo, M Collins.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is induced in the SJL/J mouse by adoptive transfer of activated proteolipid protein peptide (PLP) 139-151-specific Th1 cells. T cells responding to altered peptide ligands (APL) of PLP, previously shown to induce Th2 differentiation and regulate disease in PLP-immunized mice, do not transfer EAE. However, the exact mechanism of disease regulation by APL-specific T cells has not been elucidated. In this report, we show that 1F1, a Th2 clone specific for an APL of PLP139-151 can prevent adoptive transfer of EAE when cocultured with PLP-encephalitogenic spleen cells (PLP-spleen). Cytokines from activated 1F1 cells were detected by hybridization of mRNA to oligonucleotide arrays (DNA chip) and by ELISA. The Th2 cytokines found to be present at the highest protein and mRNA levels were evaluated for their role in suppression of adoptive transfer of EAE from PLP-activated spleen cell cultures. Abs to individual cytokines in 1F1 PLP-spleen cocultures suggested that IL-4, IL-13, and TGF-beta played a significant role in suppressing EAE. Abs to the combination of IL-4, IL-10, IL-13, and TGF-beta completely neutralized the protective effect of 1F1. Addition of Th2 cytokines to PLP-spleen cultures showed that IL-13 and TGF-beta were each individually effective and low levels of IL-4 synergized with IL-13 to inhibit disease transfer. IL-5, IL-9, and IL-10 had little or no effect whereas GM-CSF slightly enhanced EAE. Our results demonstrate that Th2 cytokines derived from APL-specific Th2 cells can effectively down-regulate the encephalitogenic potential of PLP-spleen cells if present during their reactivation in culture.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10725711     DOI: 10.4049/jimmunol.164.7.3563

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

Review 2.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 3.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

4.  Antigenic Stimulation of Kv1.3-Deficient Th Cells Gives Rise to a Population of Foxp3-Independent T Cells with Suppressive Properties.

Authors:  Inna V Grishkan; Dominique M Tosi; Melissa D Bowman; Maya Harary; Peter A Calabresi; Anne R Gocke
Journal:  J Immunol       Date:  2015-07-06       Impact factor: 5.422

5.  Natural killer type 2 bias in remission of multiple sclerosis.

Authors:  K Takahashi; S Miyake; T Kondo; K Terao; M Hatakenaka; S Hashimoto; T Yamamura
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

6.  IL-4/IL-13 Heteroreceptor Influences Th17 Cell Conversion and Sensitivity to Regulatory T Cell Suppression To Restrain Experimental Allergic Encephalomyelitis.

Authors:  Subhasis Barik; Jason S Ellis; Jason A Cascio; Mindy M Miller; Tobechukwu K Ukah; Alexis N Cattin-Roy; Habib Zaghouani
Journal:  J Immunol       Date:  2017-08-11       Impact factor: 5.422

7.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

8.  Natural killer cells control a T-helper 1 response in patients with Behçet's disease.

Authors:  Yukie Yamaguchi; Hayato Takahashi; Takashi Satoh; Yuka Okazaki; Nobuhisa Mizuki; Kazuo Takahashi; Zenro Ikezawa; Masataka Kuwana
Journal:  Arthritis Res Ther       Date:  2010-05-11       Impact factor: 5.156

9.  Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.

Authors:  P Kiptoo; B Büyüktimkin; A H Badawi; J Stewart; R Ridwan; T J Siahaan
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

10.  MicroRNA let-7e is associated with the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Hongbing Guan; Daping Fan; Davit Mrelashvili; Haiping Hao; Narendra P Singh; Udai P Singh; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Eur J Immunol       Date:  2012-11-29       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.